Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We report six patients with anti-LGI1 associated epilepsy. Two patients presented with new-onset generalized tonic-clonic seizures, four developed faciobrachial dystonic seizures and two piloerection. All patients had significant cognitive complaints at the time of diagnosis. All patients described seizure reduction during the first week of carbamazepine, and seizure freedom was obtained at a median of 13 days (range 7-22), sustained after the initiation of immunosuppression. Median time from symptom onset to carbamazepine initiation was 164 days (range 38-206 days). We discuss the particular seizure response to sodium channel blocking antiepileptic drugs, alone or associated with immunosuppression in this antibody mediated seizures.

Original publication

DOI

10.1016/j.jneuroim.2020.577268

Type

Journal article

Journal

J Neuroimmunol

Publication Date

15/08/2020

Volume

345

Keywords

Antibody mediated seizures, Autoimmune epilepsy, Carbamazepine, Leucine-rich glioma-inactivated 1 (LGI1) autoantibodies, Neuroimmunology, Adult, Aged, Ambulatory Care, Anticonvulsants, Autoantibodies, Carbamazepine, Epilepsy, Female, Humans, Intracellular Signaling Peptides and Proteins, Male, Middle Aged, Outpatients, Prospective Studies, Treatment Outcome